Advancing the next generation of precision oncology and inflammation therapeutics.
At Allterum Therapeutics, we are pioneering breakthrough medicines shaped by rigorous science, deep clinical insight, and an unwavering commitment to the patients who motivate everything we do.
Mission
We advance precision medicine
through uncompromising science and meaningful innovation—developing oncology and inflammation therapies that deliver extraordinary accuracy, transform treatment pathways, and change patient lives…because #PatientsCantWait.
Vision
We aim to set a new standard for
precision therapeutics. Our vision is to build
a world-class organization at the forefront of oncology and inflammation—accelerating discovery, elevating patient care, and expanding what's possible for people everywhere.
ABOUT US
Curiosity fuels us. Courage moves us forward.
Purpose keeps us focused.
A Brief History of 4A10
Allterum is building a novel therapeutic franchise targeting the CD127 pathway, beginning with 4A10, a monoclonal antibody directed against CD127, a key component of the IL-7 receptor complex found on T-cells and pre-B cells. CD127 signaling has been implicated in cancer cell growth, leukemia development, and chemotherapy resistance. As the first immunotherapy approach designed to target CD127, 4A10 harnesses the patient's own immune system to recognize and destroy cancer cells. 4A10 is currently in development for relapsed leukemia, with potential applications across other hematologic malignancies and solid tumors.
Developing Treatments for CD127 Expressing Cancers
With an initial focus on hematological malignancies, Allterum Therapeutics is developing 4A10, an anti-CD127 monoclonal antibody for treating acute lymphoblastic leukemia (ALL), B-cell malignancies, and lymphomas with CD127 expression. Allterum is also exploring relapsed/refractory solid tumors with CD127 expression. The 4A10 antibody was developed at the National Cancer Institute (NCI) and licensed exclusively to Fannin.
Allterum is a Fannin portfolio company. It is an early-stage life science commercialization group, which has assigned its executed license. The company is working with national leaders in cancer at Baylor College of Medicine, Texas Children’s Hospital, the NCI, the Leukemia and Lymphoma Society, and The University of Texas MD Anderson Cancer Center to develop the technology.
Continuing the Fight in Hematologic Malignancies
At Allterum, we are dedicated to advancing innovative, targeted therapies for patients facing the greatest unmet needs in oncology. While survival rates for acute lymphoblastic leukemia (ALL) have improved significantly, individuals with relapsed or refractory T-cell ALL and certain B-cell hematologic malignancies still have limited treatment options. Our mission is to develop precise, effective therapies that improve outcomes and offer new hope to the patients who need it most.
Exploring Other CD127 Expressing Cancers
Ongoing pre-clinical studies focused on lymphomas and solid tumors will extend Allterum’s clinical program to other metastatic disease with CD127 expression where the overall survival is limited given current approved therapies.
TEAM
Our people are the engine behind every breakthrough.
The Allterum team brings together expertise in drug development, biology, chemistry, and translational science, enhanced by Houston’s dynamic bio-innovation ecosystem. Through collaboration and a culture of curiosity and ambition, we are advancing the potential of precision medicine.
Chief Executive Officer
Dr. Yan Moore is a physician leader with 26 years of experience across oncology, immunology, rare disease, translational medicine, and global product development. He has led corporate strategy, portfolio prioritization, cross-functional organizations, and clinical, regulatory, partnership, and commercialization efforts, translating platform science into enterprise value and patient impact. Prior to Allterum, Dr. Moore served as CMO of Omega Therapeutics and SVP, Global Head of Oncology at Ipsen, with prior roles at Sanofi, GSK, BMS, and emerging biotechs. He holds BSc and MD degrees from Tel Aviv University’s Sackler School of Medicine, an MBA from Drexel University, and completed executive programs at Harvard Business School and London Business School.
President, Research & Development
Atul Varadhachary, MD, Ph.D., serves as a member of the Board of Directors and President R&D for Allterum Therapeutics. He served as CEO for Allterum from July 2018 to December 2024. In addition to his role at Allterum, Atul has served as the Managing Partner at Fannin since 2013. Dr. Varadhachary is an experienced biotech entrepreneur who has helped lead over a dozen development programs in oncology, including seven in clinic with one progressing to Phase 3 clinical trial.
Chief Medical Officer
Philip Breitfeld, MD is a pharmaceutical industry executive focusing on strategic drug development in oncology. He is a Pediatric Hematologist-Oncologist with a 20 year academic career spanning basic cell and molecular biology to clinical investigation. In his more than 20 years in the pharmaceutical industry, Dr. Breitfeld has leadership positions in biotech, traditional pharma, and contract research organizations.
Head of Clinical Operations
Head of Clinical Operations. Dr. Schaumberg has more than 30 years of drug development expertise, including experience with global pharmaceutical organizations, biotechnology companies and clinical research organizations. His past roles include Vice President level positions in Biotech as Senior Vice President, Clinical Operations of Agennix AG as well as Vice President level positions in the clinical research organizations PRA International and Inveresk. Jack also serves as Head of Clinical Operations for Pulmotect, Inc.
OUR SCIENCE
Pioneering Precision Medicine
CD127 to Engage Multiple Mechanisms
4A10 is designed to target CD127, a central mediator of IL-7 signaling implicated in cancer cell survival and treatment resistance. By targeting this pathway, 4A10 represents a differentiated immune-directed therapeutic approach for CD127+ malignancies. 4A10 is designed to act through various mechanisms—signal blockade, ADCC, and ADCP—combining pathway inhibition with immune-mediated mechanisms to target malignant cells.
Explore these mechanisms of action below.
Component
Information
1. Tumor cell
Expressing CD127 receptors on its surface
2. CD127 receptor
IL-7Rα target receptor located on the tumor cell
3. 4A10 (Anti-CD127 antibody )
Monoclonal antibody engineered to target CD127
4. NK cell (effector cell)
Effector immune cell that mediates ADCC
5. Fc receptor (FcγR)
Fc receptor on NK cell binding to the antibody stem
6. Cytotoxic molecules
Perforin & Granzymes released to destroy cell
1. Tumor cell expresses CD127 receptors.
The tumor cell surface is populated with CD127 receptors, marking it as the target.
Component
Information
1. Tumor cell
Expressing CD127 receptors on its surface
2. CD127 receptor
IL-7Rα target receptor located on the tumor cell
3. 4A10 (Anti-CD127 antibody )
Monoclonal antibody engineered to target CD127
4. Macrophage (phagocyte)
Immune cell that engulfs and digests the tumor cell
5. Fc receptor (FcγR)
On macrophage; binds to the Fc region of antibodies
6. Lysosome
Fuses with phagosome to digest the tumor cell
1. Tumor cell expresses CD127 receptors.
The tumor cell surface is populated with CD127 receptors, marking it as the target.
Component
Information
1. Tumor cell
Expressing CD127 target receptors on its surface
2. CD127 receptor
IL-7Rα target receptor located on the tumor cell
3. IL-7 (ligand)
Binds to CD127 receptor to deliver growth/survival signals
4. 4A10 (Anti-CD127 antibody )
Binds to CD127 on the receptor and blocks IL-7 binding
1. IL-7 Binding & Signaling
IL-7 binds to the CD127-gamma chain receptor on the tumor cell. This delivers a growth and survival signal to the tumor cell.
Component
Information
1. IL-7 Binding & Signaling
IL-7 binds to the CD127-gamma chain receptor on the tumor cell. This delivers a growth and survival signal to the tumor cell.
Targeting CD127 Biology
4A10 targets CD127, a central driver of IL-7 signaling in cancer biology.
By doing this, it is designed to block a biologically important pathway driving tumor survival and resistance.
Differentiated Mechanism
4A10 combines three mechanisms—blocking signaling, inducing ADCC, and promoting ADCP.
It is the only CD127-targeted therapy in development with ADCC capability, enhancing immune-mediated killing.
Strong Preclinical Efficacy & Safety
4A10 has demonstrated potent antitumor activity across ALL models, including chemo-resistant settings and in combination with chemotherapy. Activity also extends to other CD127-positive cancers such as AML and lymphoma. Preclinical studies showed a favorable safety and tolerability profile, with no dose-limiting toxicities observed.
Targeted Clinical Development
Clinical development is focused on relapsed/refractory ALL and lymphoblastic lymphoma, where unmet need remains high.
Allterum’s future plans include expansion into additional non-ALL hematologic malignancies and solid tumors.
PIPELINE
Our Therapeutic Pipeline
A diversified portfolio targeting high-unmet-need indications in oncology and inflammation.
Lead Program
(AML, Lymphomas, Others)
(Lung, Colorectal, Breast, Others)
Commitment to Patient Access
ALT-101 Clinical Trial Sites
Note: Currently offering access via clinical trial at participating sites.
Early Development Pipeline Programs
[Undisclosed Joint Development]
Autoimmune Disorders
[Undisclosed Joint Development]
Lead Program
Commitment to Patient Access
Note: Currently offering access via clinical trial at participating sites.
Early Development Pipeline Programs
PARTNERS
Advancing Innovation Through Collaboration
We collaborate with leading institutions and experts to advance innovative science. Together, we accelerate the development of transformative therapies.
“I am excited to work with Allterum to develop a much-needed option for the treatment of children with T-cell ALL.”
Eric Schafer, M.D; M.H.S
Lead Investigator & Associate Professor
Dept. of Pediatrics, Div. of Hematology-Oncology,
Baylor College of Medicine
“After years of research, it’s incredibly rewarding to see this antibody move closer to patients.”
Susan Rheingold, M.D.
Co-Lead Investigator
Professor of Clinical Pediatrics
Children's Hospital of Philadelphia
“After years of searching for a way to help those kids who have no effective treatment for their leukemia, I’m thrilled to see Allterum take our antibody into the clinic.”
Scott Durum, Ph.D
4A10 Inventor
Section Chief, Cytokine and Immunity Section
National Cancer Institute
Fujifilm Diosynth
Biotechnologies
Global Operations
Cancer Prevention & Research
Institute of Texas
Austin, Texas
Fannin
Innovation Studio
Houston, Texas
Worldwide Clinical Trials
Houston, Texas
LabCorp
Houston, Texas
Pharmaron
Global Operations
Catalent
Global Operations
Navitas Clinical Research
Global Operations
Navitas also provides regulatory and medical writing support, including US IND submission preparation & publishing, CMC authoring for Modules 2.3 and 3, IND lifecycle management & health authority response support, regulatory strategy guidance and clinical/non-clinical documentation development. Leveraging its integrated regulatory, medical writing and RIM capabilities, including chronology tracking through rimREADY, Navitas helps facilitate efficient regulatory execution throughout the drug development program.
Fujifilm Diosynth
Biotechnologies
Global Operations
Cancer Prevention & Research
Institute of Texas
Austin, Texas
Fannin
Innovation Studio
Houston, Texas
Worldwide Clinical Trials
Houston, Texas
LabCorp
Houston, Texas
Pharmaron
Global Operations
Catalent
Global Operations
Navitas Clinical Research
Global Operations
Navitas also provides regulatory and medical writing support, including US IND submission preparation & publishing, CMC authoring for Modules 2.3 and 3, IND lifecycle management & health authority response support, regulatory strategy guidance and clinical/non-clinical documentation development. Leveraging its integrated regulatory, medical writing and RIM capabilities, including chronology tracking through rimREADY, Navitas helps facilitate efficient regulatory execution throughout the drug development program.
NEWS
Research & Company Spotlight
CAREERS
Join Our Team
Clinical Trial Manager
Responsible for the end-to-end management and execution of clinical trials within Allterum's hematology and oncology programs. This role ensures high-quality study delivery, operational excellence, and regulatory compliance.
- Lead trial execution from protocol development through database lock
- Manage investigative site monitoring and data quality oversight
- Coordinate cross-functional teams including medical, regulatory, and biostatistics
- Maintain TMF integrity and ensure GCP compliance throughout study lifecycle
Medical Director
Provide medical leadership and scientific oversight for Allterum's clinical-stage oncology portfolio, guiding protocol design, safety monitoring, and health authority interactions.
- Lead medical oversight and safety monitoring for Phase 1/2 clinical studies
- Author and review clinical trial protocols, investigator brochures, and IND/BLA sections
- Engage key opinion leaders (KOLs) and principal investigators across trial sites
- Collaborate with translational sciences to advance biomarker-driven trial strategies
Vice President, R&D
Provide strategic vision and executive leadership for Allterum's research and development programs, guiding scientific operations and advancing our therapeutic pipeline through critical preclinical and clinical milestones.
- Direct comprehensive R&D strategy across oncology and hematology portfolios
- Oversee preclinical efficacy, pharmacology, and IND-enabling safety studies
- Lead, mentor, and expand a high-performing team of research scientists
- Collaborate with the executive team and board of directors to shape corporate strategy